Price
$64.04-6.82%Social Signal Score
Analyst Ratings
17 analysts52-week range
- Last close
- $64.04
- Off 52w high
- -38.0%
- 200-day average
- $56.56
- vs 200-day
- +13.2%
Revenue
$411.54M+2160.01%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Lefkofsky
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 3,800
- Beta
- 3.61
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.28
Financials
Revenue
$411.54M+2160.0%Net Income
$-14.85MEBITDA
$20.48MFree Cash Flow
$-5.54MEPS (diluted)
$-0.08Shares Outstanding (diluted)
181.31M+189.1%Operating Expenses
$323.56MCash & Debt
$637.35MReturn of Capital
$0.00Revenue by Segment (annual)
$955.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.27B | $-245.03M | $-1.41 |
| 2024 | $693.40M | $-705.81M | $-4.60 |
| 2023 | $531.82M | $-214.12M | $-1.73 |
| 2022 | $320.67M | $-289.81M | $-1.97 |
| 2021 | $257.85M | $-259.19M | $-1.75 |
| 2020 | $188.00M | $-209.85M | $-1.49 |
| 2019 | $62.06M | $-114.95M | $-0.92 |
Valuation
TEMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
78+31.91%Social Signal Score
Mentions (79)
- News (RSS)fool·3d ago·Positive
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027? Natera's revenue growth tops 37%, but Tempus AI trades at a lower forward multiple, and the balance sheets and cash flow stories diverge sharply.
View source ↗ - Newsfool.com·3d ago·Positive
Tempus AI: 3 Key Takeaways for Long-Term Investors Tempus signed data agreements expected to generate $193 million over 5 years. Approved pricing moves will add $80 million in oncology ASP during 2027.
View source ↗ - Newsprnewswire.com·12d ago·Neutral
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer Dare to Dream Project will build a real-world data set that can inform pediatric AML research and future clinical trials while helping families better understand their health information WASHINGTON, Nov. 10, 2026 /PRNewswire/ -- Blood Cancer United® today announced the launch of Dare to Dream REALworld: AML, a patient-centered initiative co-founded with Rally Foundation for Childhood Cancer Re
View source ↗ - Newsprnewswire.com·13d ago·Neutral
…r SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation , a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-en…
View source ↗ - News (RSS)seekingalpha·14d ago·Neutral
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up
View source ↗ - Newsseekingalpha.com·15d ago·Negative
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up Tempus is rated 'hold' as current valuation already prices in considerable future success. The platform's core strength lies in connecting diagnostic data with clinical outcomes, enhancing research value and recurring revenue potential. Q3 2026 showed strong revenue growth in both Diagnostics (+20%) and Data & Applications (+33%), with improving adjusted EBITDA but persistent GAAP losses.
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)
View source ↗ - Newsseekingalpha.com·18d ago·Negative
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis) Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data & Applications revenue accelerated to 33% growth. Major partnerships with Bristol Myers Squibb, Moderna, and Merck validate TEM's strategic positioning in AI-driven medicine.
View source ↗ - Newsmarketbeat.com·19d ago·Positive
Tempus AI Surges on Earnings Beat, But Can the Rally Last? Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the path to profitability, cash burn, and immense opportunity.
View source ↗ - Newszacks.com·19d ago·Positive
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.
View source ↗ - News (RSS)seekingalpha·20d ago·Neutral
Tempus AI, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News247wallst.com·20d ago·Negative
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsbenzinga.com·20d ago·Neutral
Tempus AI Says It Is Uniquely Positioned Tempus AI Inc. (NASDAQ:TEM) shares were trading higher on Monday after the company reported third-quarter adjusted earnings of 7 cents per share, swinging from a loss of 8 cents, beating the consensus per-share loss of 11 cents.
View source ↗ - Newszacks.com·20d ago·Neutral
Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·20d ago·Neutral
Tempus AI (TEM) Beats Q3 Earnings and Revenue Estimates Tempus AI (TEM) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.11 per share a year ago.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
What Tempus AI (TEM) Said on Its Q3 Earnings Call Tempus AI NASDAQ: TEM reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also raised its full-year revenue outlook and said it generated positive adjusted EBITDA during the quarter.
View source ↗ - Newsfool.com·20d ago·Neutral
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction Data and Applications revenue grew 33% and earns gross margins above 71%, so its faster growth lifts company-wide margins. The adjusted EBITDA outlook held at about $65 million, implying a jump to roughly $34 million in Q4 that investors should verify.
View source ↗ - Newsbarrons.com·20d ago·Negative
Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer Tempus AI reported better-than-expected third-quarter earnings.
View source ↗ - News (RSS)investing·22d ago·Neutral
Cathie Wood’s ARK sells Eli Lilly stock, buys Tempus AI and Coinbase
View source ↗ - Newszacks.com·23d ago·Neutral
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now? Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.
View source ↗ - News (RSS)investing·23d ago·Positive
Cathie Wood’s ARK sees strong interest in Cerebras stock, trims Tempus AI
View source ↗ - Newszacks.com·27d ago·Neutral
Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - News (RSS)seekingalpha·30d ago·Positive
Tempus AI: Less Risky Than When I Said Buy
View source ↗ - News (RSS)channelnewsasia·30d ago·Negative
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
View source ↗ - News (RSS)seekingalpha·30d ago·Neutral
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Tempus AI: Less Risky Than When I Said Buy Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow, with adjusted EBITDA turning positive. The Personalis acquisition secures MRD capabilities, integrating high-demand data and supporting pharma partnerships, while xT CDx FDA approval enables significant pricing uplift from 2027. The Data and Applications segment maintains robust ~28% growth, with a growing backlog and margins stabilizing despite headl…
View source ↗ - Newszacks.com·34d ago·Neutral
Here's How Tempus AI Demonstrates Improving Operating Leverage TEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.
View source ↗ - Newsbusinesswire.com·40d ago·Negative
…or Rare Diseases ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext™ and GenomeReveal™, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases. Many patients and families undergo years of testing without a diagnosis, and even comprehensive genetic testing can miss or be unable to interpre…
View source ↗ - Newszacks.com·41d ago·Neutral
Tempus AI Expands Strategic Collaborations to Drive Future Growth TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.
View source ↗ - Newszacks.com·44d ago·Neutral
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock, but premium valuation and reimbursement risks warrant caution.
View source ↗ - News (Marketaux)gurufocus.com·47d ago·Neutral
BTIG Downgrades Personalis (PSNL) to Neutral Amid Acquisition by Tempus AI The recent downgrade by BTIG follows the[+187 characters]
View source ↗ - Newszacks.com·48d ago·Negative
Here's How Tempus AI is Capitalizing on AI-ECG Market Growth TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.
View source ↗ - Newsbusinesswire.com·52d ago·Neutral
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year's congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid…
View source ↗ - 4chan /biz/biz·54d ago·Negative
>>62735271 Not buying anything for the next 2 weeks will comparatively make you more than most investments. Once the cheapies appear and pink wojaks flood the catalogue, when smiggers are suiciding in their droves only then I will be slurping: MU, SNDK, NVDA, WDC, RDDT, META, AVGO, TSMC, NBIS, SKHY, BLOOM, ARM, PENG, GRRR, GRAB, CRDO, SMCI, TEM, POET
View source ↗ - News (RSS)seekingalpha·55d ago·Positive
Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike
View source ↗ - News (RSS)fool·59d ago·Negative
Tempus AI Chief Accounting Officer Sells $529,650 of Stock Sale follows 30% rebound in the stock year to date.
View source ↗ - Newsnewsfilecorp.com·59d ago·Neutral
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin A…
View source ↗ - News (RSS)yahoo·61d ago·Neutral
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
View source ↗ - News (RSS)seekingalpha·61d ago·Neutral
Tempus AI: High Risk, But With A Great Cause
View source ↗ - Newsseekingalpha.com·61d ago·Negative
Tempus AI: High Risk, But With A Great Cause Tempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth. TEM's acquisition of Personalis fills a critical MRD monitoring gap, unlocking recurring revenue and enhancing AI data assets. Q2 2026 saw 22% revenue growth, improved margins, and raised full-year guidance, despite continued operating losses.
View source ↗ - News (RSS)seekingalpha·61d ago·Neutral
Tempus AI: Data And Applications Will Unlock More Upside
View source ↗ - Newsseekingalpha.com·61d ago·Positive
Tempus AI: Data And Applications Will Unlock More Upside Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025, validating the Personalis acquisition. Data & applications segment led Q2 growth at 28%, with strong bookings and AI innovation positioning the company for long-term growth and margin expansion.
View source ↗ - Newsmarketbeat.com·62d ago·Positive
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion Tempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.
View source ↗ - News (RSS)seekingalpha·62d ago·Neutral
Tempus AI: Market Is Hyping On An Uncertain Number
View source ↗ - Newsinvezz.com·65d ago·Positive
Tempus AI stock is soaring: does it have more upside to go? Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization above $14 billion.
View source ↗ - Newszacks.com·65d ago·Neutral
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength? Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
View source ↗ - Newsyoutube.com·69d ago·Neutral
Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI Eric Lefkofsky, Tempus AI founder and CEO, joins 'The Exchange' to discuss AI's role in healthcare, advancing cancer research with AI, personalized vaccines, and more.
View source ↗ - News (RSS)investing·72d ago·Neutral
Tempus AI plans 100,000 whole genome sequencing dataset
View source ↗ - Newsbusinesswire.com·72d ago·Positive
…us Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically …
View source ↗ - News (RSS)barrons·79d ago·Neutral
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.
View source ↗ - News (RSS)wsj·79d ago·Neutral
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.
View source ↗ - News (RSS)yahoo·80d ago·Neutral
Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?
View source ↗ - News (RSS)investing·82d ago·Positive
Tempus AI stock rises on Piper Sandler upgrade to Overweight
View source ↗ - Newsdefenseworld.net·85d ago·Neutral
Artificial Intelligence Stocks To Follow Today – August 27th Tempus AI, Hut 8, SentinelOne, SoundHound AI, Upstart, Fluence Energy, and BigBear.ai are the seven Artificial Intelligence stocks to watch today, according to MarketBeat's stock screener tool. Artificial intelligence stocks are shares of publicly traded companies that develop, provide, or significantly use AI technologies, such as machine learning, generative AI, robotics, or related hardware and
View source ↗ - News (RSS)yahoo·87d ago·Neutral
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
View source ↗ - News (RSS)zerohedge·87d ago·Neutral
…unvaccinated. Bogen and her department did say that not all deaths are referred to a coroner under Pennsylvania law. A thin-section transmission electron micrograph (TEM) reveals the ultrastructural appearance of a single virus particle, or "virion", of measles virus. CDC via Getty Images State law says that any deaths "known or suspected to be due to contagious disease and constituting a public hazard" shall be investigated by a coroner. State officials also encouraged people to take the measle…
View source ↗ - Newsbenzinga.com·90d ago·Neutral
What's Going On With Tempus AI Stock on Monday? Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.
View source ↗ - News (RSS)seekingalpha·92d ago·Positive
Tempus AI: Winning With Precision Medicine
View source ↗ - News (RSS)yahoo·92d ago·Neutral
What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing
View source ↗ - News (RSS)yahoo·92d ago·Neutral
Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened
View source ↗ - News (RSS)fool·92d ago·Positive
Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.
View source ↗ - News (RSS)yahoo·92d ago·Neutral
Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.
View source ↗ - News (RSS)fool·92d ago·Negative
What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.
View source ↗ - News (RSS)fool·92d ago·Neutral
Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.
View source ↗ - News (RSS)fool·92d ago·Neutral
Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter. This sale was non-discretionary, executed to cover tax withholding from RSU vesting.
View source ↗ - News (RSS)fool·92d ago·Neutral
Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.
View source ↗ - Newsseekingalpha.com·92d ago·Positive
Tempus AI: Winning With Precision Medicine Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus.
View source ↗ - Newsfool.com·92d ago·Neutral
A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know The transaction involved 3,000 shares with a value of $161,700 on August 14. The sale reduced West's direct equity position by 8%.
View source ↗ - Newsfool.com·92d ago·Positive
Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds. The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.
View source ↗ - Newsfool.com·92d ago·Neutral
Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know These 6,175 shares were disposed of at a weighted average price of $49.61 per share, for a total transaction value of $306,342. The transaction was a "sell to cover" event executed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.
View source ↗ - Newsfool.com·92d ago·Neutral
What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing The transaction involved 48,842 shares with an estimated value of about $2.7 million. This was a non-discretionary transaction executed to cover tax withholding obligations associated with the vesting of restricted stock units.
View source ↗ - Newsfool.com·92d ago·Negative
Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened The transactions involved 17,314 shares at a weighted average price of $53.71 per share, totaling $930,000. The sales were executed directly by Schoenherr and were primarily structured to satisfy tax withholding obligations.
View source ↗ - Newsfool.com·92d ago·Neutral
Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter. The transaction involved 41,095 shares executed at a weighted average price of $49.61 per share, representing a total value of $2.0 million. The sale was non-discretionary, executed to cover tax obligations associated with the vesting of restricted stock units, and does not reflect the insider's view on the stock.
View source ↗ - Newsfool.com·92d ago·Positive
Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know The disposition of 133,000 shares was executed at a weighted average price of $49.61 per share, representing a total transaction value of about $6.6 million. The activity was non-discretionary, performed solely to satisfy statutory tax withholding obligations associated with the vesting of restricted stock units.
View source ↗ - Newsseekingalpha.com·96d ago·Neutral
Tempus AI: The Data Flywheel Has Started Spinning Tempus AI reported its first GAAP profit, accelerated data business growth, and raised 2026 revenue guidance to $1.595B–$1.605B (+25% Y/Y). Operating leverage from oncology volume and a mix shift to high-margin Data & Apps (72%-75% GM) drove profitability improvement and narrowed cash outflows. FDA approval for xT CDx and higher xF liquid biopsy ASPs is expected to add ~$400M incremental revenue by 2028, with the Personalis acquisition targeting …
View source ↗ - Newsnewsfilecorp.com·96d ago·Negative
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies Agreement transitions previously announced LOI into a definitive commercial relationship First bulk commercial order fulfilled for distribution into clinics and pharmacies TempraMed expands access to its temperature-protection solutions through healthcare channels in Panama Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd…
View source ↗ - Newszacks.com·101d ago·Positive
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.
View source ↗ - Newszacks.com·103d ago·Positive
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $0.06 per share
Typical surprise +36.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$0.07 vs $-0.09beat
- Thu, Jul 30$-0.04 vs $-0.14beat
- Tue, May 5$-0.13 vs $-0.21beat
- Tue, Feb 24$-0.04 vs $-0.04beat
- Tue, Nov 4$-0.11 vs $-0.17beat
- Fri, Aug 8$-0.22 vs $-0.23beat
Estimates and results for TEM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TEM officers and directors.
- Bought
- —
- Sold
- $74.2m
0 trades
99 trades
- Polovin Andrewsold
- Polovin Andrewsold
- Polovin Andrewsold
- Lefkofsky Eric Psold
- Lefkofsky Eric Psold
- Lefkofsky Eric Psold
- Rogers James Williamsold
- Rogers James Williamsold
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Nancy Pelosihouse · CA11 · disclosed Jan 23, 2026 (7d later)Buy$50,001 - $100,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (32d later)Buy$1,001 - $15,000
- Nancy Pelosihouse · CA11 · disclosed Jan 17, 2025 (3d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
